Literature DB >> 2841246

Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus.

C D Gregory1, C F Edwards, A Milner, J Wiels, M Lipinski, M Rowe, T Tursz, A B Rickinson.   

Abstract

Epstein-Barr virus (EBV) is causally linked with endemic Burkitt's lymphoma (BL), a tumor whose homogeneous cell surface phenotype suggests derivation from a particular subset of activated germinal centre B cells in vivo. Endemic BL also shows an unusual form of EBV infection with down-regulation of certain of the virus latent proteins which are constitutively expressed when EBV infects and transforms normal resting B cells in vitro. Here we question whether this virus:cell interaction is unique to malignant BL cells or whether it might be reproduced by in vitro infection of those particular germinal centre cells displaying the BL-like phenotype. Firstly, we show by biochemical means that a subset of normal tonsillar B cells does indeed express the globotriaosylceramide glycolipid BLA and the common acute lymphoblastic leukaemia antigen CALLA, 2 important markers of the BL phenotype. Secondly, using 2-colour immunofluorescence labelling with anti-BLA and anti-CALLA monoclonal antibodies (MAbs), 4 subsets of low buoyant density tonsillar B cells (BLA+ CALLA+, BLA+ CALLA-, BLA- CALLA+, BLA- CALLA-) have been separated by means of a FACS and tested for their susceptibility to EBV-induced growth transformation in a limiting dilution assay. The BLA+ CALLA+ (i.e., BL-like) subset contained the highest proportion of cells already actively in cycle in vivo and gave the lowest yield of transformants, perhaps reflecting the greater efficiency with which EBV transforms resting target cells. Of the cell lines established from the BLA+ CALLA+ population, a significant number retained BLA expression but CALLA was always lost. In 2 further respects, these lines resembled conventional in vitro transformants rather than lines of BL type; thus the cells expressed cellular "activation" antigens (CD23, CD39, CD30, Ki-24) characteristic of the lymphoblastoid phenotype and contained the full spectrum of EBV latent proteins.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2841246     DOI: 10.1002/ijc.2910420212

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Transforming growth factor beta-induced reactivation of Epstein-Barr virus involves multiple Smad-binding elements cooperatively activating expression of the latent-lytic switch BZLF1 gene.

Authors:  Tawin Iempridee; Shreyasi Das; Iris Xu; Janet E Mertz
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

2.  Globotriaosyl ceramide modulates interferon-alpha-induced growth inhibition and CD19 expression in Burkitt's lymphoma cells.

Authors:  M D Maloney; B Binnington-Boyd; C A Lingwood
Journal:  Glycoconj J       Date:  1999-12       Impact factor: 2.916

3.  Epstein-barr virus-induced changes in B-lymphocyte gene expression.

Authors:  Kara L Carter; Ellen Cahir-McFarland; Elliott Kieff
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 4.  Epstein-Barr virus infection and associated diseases in children. I. Pathogenesis, epidemiology and clinical aspects.

Authors:  V Schuster; H W Kreth
Journal:  Eur J Pediatr       Date:  1992-10       Impact factor: 3.183

Review 5.  Gamma herpesviruses: pathogenesis of infection and cell signaling.

Authors:  J Rajcáni; M Kúdelová
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

6.  Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors.

Authors:  M Birkenbach; K Josefsen; R Yalamanchili; G Lenoir; E Kieff
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

7.  Distinct ex vivo susceptibility of B-cell subsets to epstein-barr virus infection according to differentiation status and tissue origin.

Authors:  Marcus Dorner; Franziska Zucol; Christoph Berger; Rahel Byland; Gregory T Melroe; Michele Bernasconi; Roberto F Speck; David Nadal
Journal:  J Virol       Date:  2008-03-05       Impact factor: 5.103

8.  Effects of targeting sumoylation processes during latent and induced Epstein-Barr virus infections using the small molecule inhibitor ML-792.

Authors:  Peter Garcia; Abigail Harrod; Shruti Jha; Jessica Jenkins; Alex Barnhill; Holden Lee; Merritt Thompson; Jordan Pringle Williams; James Barefield; Ashton Mckinnon; Persia Suarez; Ananya Shah; Angela J Lowrey; Gretchen L Bentz
Journal:  Antiviral Res       Date:  2021-02-10       Impact factor: 5.970

Review 9.  Shiga toxin and its use in targeted cancer therapy and imaging.

Authors:  Nikolai Engedal; Tore Skotland; Maria L Torgersen; Kirsten Sandvig
Journal:  Microb Biotechnol       Date:  2011-01       Impact factor: 5.813

10.  Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts.

Authors:  P Merville; J Déchanet; A Desmoulière; I Durand; O de Bouteiller; P Garrone; J Banchereau; Y J Liu
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.